Wiseman E H, Chang Y H, Lombardino J G
Arzneimittelforschung. 1976;26(7):1300-3. doi: 10.1002/chin.197641380.
Piroxicam (CP-16 171) is a potent acidic anti-inflammatory agent structurally distinct from the current agents such as indometacin, phenylbutazone or naproxen. Pharmacokinetic studies indicate a longer plasma half-ife for piroxicam than for these agents. Potency in the range of indometacin is observed when piroxicam is tested in the carrageenan rat paw edema model. This activity is not dependent on an intact adrenocorticoid system. The high potency, long half-life and absence of cardiovascular or cental nervous system effects have encouraged clinical trial of piroxicam.
吡罗昔康(CP - 16 171)是一种强效酸性抗炎药,其结构与目前的药物如吲哚美辛、保泰松或萘普生不同。药代动力学研究表明,吡罗昔康的血浆半衰期比这些药物更长。当在角叉菜胶诱导的大鼠足肿胀模型中测试吡罗昔康时,观察到其效力与吲哚美辛相当。这种活性不依赖于完整的肾上腺皮质系统。其高效力、长半衰期以及无心血管或中枢神经系统作用促使了对吡罗昔康进行临床试验。